Evidence map›Paper›PMID 35641170›Full record

ArticleStem cells translational medicine2022

Definition and Characteristics of Mesenchymal Stromal Cells in Preclinical and Clinical Studies: A Scoping Review.

Laurent Renesme, Maria Pierro, Kelly D Cobey, Rhea Mital, Kennedy Nangle, Risa Shorr, Manoj M Lalu, Bernard Thébaud

Abstract readScoping Review
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cells translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Stem Cells in Aging and Anti-Aging.Stem cell reviews and reports · 2026
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Laurent RenesmeRegenerative Medicine Program, The Ottawa Hospital Research Institute, Ottawa, ON, Canada.ORCID 0000-0001-6848-3617
Maria PierroNeonatal and Paediatric Intensive Care Unit, M. Bufalini Hospital, AUSL Romagna, Cesena, Italy.ORCID 0000-0002-5451-6702
Kelly D CobeyCentre for Journalology, Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, ON, Canada.ORCID 0000-0003-2797-1686
Rhea MitalRegenerative Medicine Program, The Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Kennedy NangleRegenerative Medicine Program, The Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Risa ShorrCentre for Journalology, Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Manoj M LaluRegenerative Medicine Program, The Ottawa Hospital Research Institute, Ottawa, ON, Canada.ORCID 0000-0002-0322-382X
Bernard ThébaudRegenerative Medicine Program, The Ottawa Hospital Research Institute, Ottawa, ON, Canada.ORCID 0000-0003-1844-7145

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stromal cells (MSCs) are widely used in preclinical and clinical research. Despite minimal criteria to define MSCs provided by the International Society for Cell and Gene Therapy (ISCT), concerns have been raised about inconsistent descriptions of cell products used. To address the question "How are MSCs currently defined and characterized?" we conducted a scoping review on original MSC preclinical and clinical studies published over a 3-month period. Selected studies identified from a systematic search of MEDLINE and Embase were categorized as follows: Clinical, Animal, Biology, or Biomaterial studies. Data were extracted from a randomly selected subsample of studies. We extracted information, including epidemiological characteristics of studies, study design, ISCT criteria, and MSC characterization and culture condition. A total of 1053 articles were included and among them, 318 articles were analyzed. Overall, 18% of the articles explicitly referred to the ISCT minimal criteria for MSC. MSC characteristics and culture conditions were inconstantly reported (eg, viability assay reported in only 18% of the articles). Only 20% of documents reported at least 1 functional assay. Clinical studies showed inconsistent completeness in reporting relevant information on the MSC characterization and cell manufacturing processes. These results suggest that further development and implementation of a consensus definition of MSCs and reporting guidelines are needed to enhance rigor, reproducibility, and transparency in MSC research.

Indexed as

Mesenchymal Stem CellsAnimalsBiocompatible MaterialsCell- and Tissue-Based TherapyGenetic TherapyReproducibility of ResultsBiocompatible Materialsclinical studiesmesenchymal stromal cellMSC characteristicsMSC definitionpreclinicalscoping review

Identifiers

PMID35641170
PMCPMC8895491

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.